MatchMedi
한국어

Patient pathway

Search trials before the next treatment line

A pathway for searching registries before a treatment decision closes doors.

What this situation means

  • Trial timing can matter because prior treatments, waiting periods, and disease sites may affect whether a trial fits.

What not to assume

  • A trial listing match does not mean the trial fits.

Information to gather

  • Cancer subtype
  • mutation report
  • prior treatments
  • current country/location
  • performance status questions for the team

Bring to the surgeon

  • Would a biopsy be needed for trial screening?

Bring to the oncologist

  • Which trials should we search before starting the next treatment?
  • Which terms should we use?

Bring to the trial team

  • Does the trial listing actually match this case?
  • Is the site recruiting now?

Related database records

Related treatment pages

clinical-trial

Clinical trials in melanoma

Trial listings can show studies that mention a cancer, mutation, drug, or treatment history, but a listing match does not mean a study fits.

clinical-trial

Clinical trials in melanoma

Trial listings can show studies that mention a cancer, mutation, drug, or treatment history, but a listing match does not mean a study fits.

immunotherapy

Lifileucel / TIL therapy

TIL therapy is different from ordinary checkpoint immunotherapy. A tumor sample is used to grow a patient's own immune cells outside the body, then the cells are given back through a specialized treatment program.

Related trial leads

A trial record is a lead only. The trial team must confirm whether it fits.

Phase 1/2 · completed

NCT03973151

Primary early clinical trial record for HL-085/tunlametinib in NRAS-mutant advanced melanoma.

This record is not the exact tunlametinib plus nivolumab combination remembered by the user.

Phase 3 · recruiting

NCT06008106

Phase III comparator trial after prior immunotherapy; useful for duration-of-response and trial-timing questions.

A trial listing match does not mean the trial fits. The trial team must confirm.

Phase 1 · unknown

NCT04835805

A sourced NRAS melanoma trial lead after anti-PD-1/PD-L1 therapy that may explain a remembered MEK/RAF plus PD-1 trial concept.

This is belvarafenib/cobimetinib/nivolumab, not tunlametinib/nivolumab.

Phase 1/2 · completed

NCT03979651

NRAS melanoma research lead involving MEK inhibition and autophagy inhibition.

Trial record does not make this a routine treatment option.

Related cohort threads

Sources with the medical details

  1. Tunlametinib Capsules approved with conditions for marketing by China NMPA. Accessed 2026-05-20.
  2. First-in-human phase I dose-escalation and dose-expansion trial of HL-085 in advanced melanoma harboring NRAS mutations. Accessed 2026-05-20.
  3. NCT03973151: Study of HL-085 in NRAS Mutant Advanced Melanoma. Accessed 2026-05-20.
  4. NCT06008106: Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma. Accessed 2026-05-20.
  5. NCT04835805: Belvarafenib alone or with cobimetinib or cobimetinib plus nivolumab in NRAS-mutant advanced melanoma. Accessed 2026-05-20.
  6. NCT03979651: Trametinib plus hydroxychloroquine in metastatic or unresectable NRAS melanoma. Accessed 2026-05-20.
  7. FDA grants accelerated approval to lifileucel for unresectable or metastatic melanoma. Accessed 2026-05-20.
  8. Drugs Approved for Melanoma. Accessed 2026-05-20.